Table 1. Characteristics of the 232 QLFT Study Subjects Compared to the Remaining 913 HALT-C Patients Treated with PEG/RBV.
| QLFT N = 232 | HALT-C N = 913 | Fisher Exact or T-test p-value | |||
|---|---|---|---|---|---|
| Mean or % | ±SD | Mean or % | ±SD | ||
| Demographics | |||||
| Age | 49.8 | 7.2 | 49.9 | 7.3 | .78 |
| BMI (kg/m2) | 29.5 | 4.9 | 29.8 | 5.6 | .40 |
| Male (%) | 75% | 71% | .25 | ||
| African American (%) | 10% | 17% | .01 | ||
| Disease Severity | |||||
| Cirrhosis (%) | 40% | 37% | .50 | ||
| Esophageal varices (%) | 35% | 22% | <0.0001 | ||
| Splenomegaly (%) | 37% | 29% | .04 | ||
| HCV Characteristics | |||||
| Genotype 1 (%) | 92% | 88% | .16 | ||
| HCV RNA (log10 IU/ml) | 6.41 | 0.50 | 6.42 | 0.54 | .78 |
| Standard Laboratory Tests | |||||
| Bilirubin (mg/dl) | 0.7 | 0.4 | 0.8 | 0.4 | .07 |
| Albumin (g/dl) | 3.76 | 0.40 | 3.92 | 0.38 | <0.0001 |
| Prothrombin time (INR) | 1.02 | 0.10 | 1.04 | 0.11 | .01 |
| Platelet Count (10−3/μL) | 169 | 66 | 169 | 64 | .99 |
| Treatment Outcomes | |||||
| SVR (%) | 14% | 16% | .42 | ||
| > 80% PEG and RBV during the first 20 Weeks (%) | 58% | 51% | .09 | ||
Abbreviations: QLFT, quantitative liver function test; HALT-C, Hepatitis C Antiviral Long-Term Treatment to Prevent Cirrhosis Trial; SD, standard deviation; PEG/RBV, peginterferon/ribavirin; BMI, body mass index; SVR, sustained virologic response.